Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or quantitative synthesis
PubMed 34655433 · doi:10.1007/s40487-021-00168-y
What was done
This narrative review summarizes clinical, epidemiological, pathophysiological, diagnostic, preventive, and treatment evidence regarding chemotherapy-induced peripheral neuropathy (CIPN).
What was found
The abstract provides no numerical data or quantitative synthesis. It reports that platinum agents (notably oxaliplatin), taxanes, vinca alkaloids, bortezomib, and thalidomide are the primary causative classes. Symptoms may persist, worsen after cessation (coasting), or partially attenuate. The review notes that diagnosis remains largely subjective, reliable risk-stratification is lacking, and trials have consistently failed to establish proven preventive or disease-modifying therapies for CIPN.
Why it matters
CIPN frequently causes chemotherapeutic dose reductions or discontinuations, compromising oncology care, yet clinicians still lack validated preventive options or objective diagnostic tools.
Limits
As a non-systematic narrative review, it is vulnerable to selection bias and provides no independent data or statistical pooling. The abstract lacks empirical numbers, effect sizes, and specific evaluation metrics for the cited management strategies.
Cited by
- supports Platinum-based chemotherapies have a higher incidence of nerve damage compared to other chemotherapy types.
- supports For certain chemotherapeutic agents, 80% to 90% of patients are expected to develop peripheral neuropathy.